Investigation Report on China's Paroxetine Market 2015.
DUBLIN, Aug. 17, 2015 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/pzk6vh/investigation) has announced the addition of the "Investigation Report on China's Paroxetine Market, 2010-2019" report to their offering.
As a drug of the selective serotonin reuptake inhibitor (SSRI) type, paroxetine is mainly used for the treatment of depression, obsessive-compulsive disorder and social anxiety and is among one of the three SSRI drugs with certain efficacy (the other two being fluoxetine and paroxetine).
Paroxetine developed fast after entering China despite a slight decline in 2014, with annual sales value rising from less than CNY 60 million in 2005 to CNY 204 million in 2013 and CAGR during this period reaching up to 17.3%. Sino-American Tianjin Smith Kline & French Laboratories Ltd, GlaxoSmithKline plc (CA), Beijing Wansheng Pharmaceutical Co., Ltd, Zhejiang Huahai Pharmaceutical Co., Ltd and Zhejiang Jianfeng Pharmaceutical Holdings occupy the majority of the Chinese market, among which Sino-American Tianjin Smith Kline & French Laboratories Ltd had the largest market share of about 69% for sales value in 2014.
With the increased mental pressure brought about by the economic development and lifestyle changes, the number of depression patients keeps growing too. Therefore, the market size of paroxetine is expected to expand in the next few years in China.
Key Topics Covered:
1 Related Concepts of Paroxetine
2 Market Profile of Paroxetine in China
3 Survey on Sales Status of Paroxetine in China, 2010-2014
4 Survey o Market Share of Major Manufacturers of Paroxetine in China, 2010-2014
5 Survey on Dosage Forms of Paroxetine in China, 2010-2014
6 Reference Price of Paroxetine in Chinese Hospitals in 2014
7 Major Manufacturers of Paroxetine in Chinese Market, 2010-2014
8 Market Outlook of Paroxetine in China, 2015-2019
- Sino-American Tianjin Smith Kline & French Laboratories Ltd
- Beijing Wansheng Pharmaceutical Co., Ltd
- Zhejiang Huahai Pharmaceutical Co., Ltd
- Zhejiang Jianfeng Pharmaceutical Holdings
For more information visit
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Publication:||PR Newswire Europe|
|Date:||Aug 17, 2015|
|Previous Article:||China's Fertilizer Market Review & Outlook Outline 2015.|
|Next Article:||China's Polyene Phosphatidyl Choline Market Investigation Report 2010-2019.|